1. Goldenberg MM. Multiple sclerosis review. PT. 2012;37:175-184.
2. Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med. 2016;16(Suppl 6):s53-s9.
3. Perrin Ross A. Management of multiple sclerosis. Am J Managed Care. 2013;19(16 Suppl):s301-s306.
4. Batalden M, Batalden P, Margolis P, et al. Coproduction of healthcare service. BMJ Qual Saf. 2016;25:509-517.
5. Chen J, Ou L, Hollis SJ. A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res. 2013;13:211.
6. Knaup C, Koesters M, Schoefer D, et al. Effect of feedback of treatment outcome in specialist mental healthcare: meta-analysis. Br J Psychiatr. 2009;195:15-22.
7. Dudgeon D. The impact of measuring patient-reported outcome measures on quality of and access to palliative care. J Palliat Med. 2018;21(S1):S76-s80.
8. Snyder CF, Herman JM, White SM, et al. When using patient-reported outcomes in clinical practice, the measure matters: a randomized controlled trial. J Oncol Pract. 2014;10:e299-e306.
9. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79.
10. de Jong MJ, Huibregtse R, Masclee AAM, et al. Patient-reported outcome measures for use in clinical trials and clinical practice in inflammatory bowel diseases: a systematic review. Clin Gastroenterol Hepatol. 2018;16:648-663.
11. Roman D, Osborne-Stafsnes J, Amy CH, et al. Early lessons from four ‘aligning forces for quality’ communities bolster the case for patient-centered care. Health Affairs. 2013;32:232-241.
12. Ehde DM, Alschuler KN, Sullivan MD, et al. Improving the quality of depression and pain care in multiple sclerosis using collaborative care: The MS-care trial protocol. Contemporary Clinical Trials. 2018;64:219-229.
13. Lavallee DC, Chenok KE, Love RM, et al. Incorporating patient-reported outcomes into health care to engage patients and enhance care. Health Affairs. 2016;35:575-582.
14. Schick-Makaroff K, Thummapol O, Thompson S, et al. Strategies for incorporating patient-reported outcomes in the care of people with chronic kidney disease (PRO kidney): a protocol for a realist synthesis. Clin Gastroenterol Hepatol. 2018;16:648-663.
15. Nelson EC, Dixon-Woods M, Batalden PB, et al. Patient focused registries can improve health, care, and science. BMJ. 2016;354:i3319.
16. Oliver BJ, Nelson EC, Kerrigan CL. Turning feed-forward and feedback processes on patient-reported data into intelligent action and informed decision-making: case studies and principles. Med Care. 2019;57 Suppl 1:S31-s37.
17. Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: A new era in clinical research. Perspect Clin Res. 2011;2:137-144.
18. Epstein RM, Street RL, Jr. The values and value of patient-centered care. Ann Fam Med. 2011;9:100-103.
19. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med. 1992;35:1505-1509.
20. Borgaonkar MR, Irvine EJ. Quality of life measurement in gastrointestinal and liver disorders. Gut. 2000;47:444-454.
21. Macdonell R, Nagels G, Laplaud DA, et al. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. Multiple Sclerosis. 2016;22:944-954.
22. Hobart J, Freeman J, Lamping D, et al. The SF-36 in multiple sclerosis: why basic assumptions must be tested. J Neurol Neurosurg Psychiatry. 2001;71:363-370.
23. Lins L, Carvalho FM. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med. 2016;4:2050312116671725.
24. Parkinson’s Disease Society of the United Kingdom. The Parkinson’s Disease Questionnaire (PDQ-39). https://www.parkinsons.org.uk/professionals/resources/parkinsons-disease-questionnaire-pdq-39 . Accessed October 20, 2019.
25. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362:865-869.
26. Calvert M, Brundage M, Jacobsen PB, et al. The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice. Health Qual Life Outcomes. 2013;11:184.
27. Black N. Patient reported outcome measures could help transform healthcare. BMJ. 2013;346:f167.
28. Franks P, Fiscella K, Shields CG, et al. Are patients’ ratings of their physicians related to health outcomes? Ann Fam Med. 2005;3:229-234.
29. Hostetter M, Klein S. Using patient-reported outcomes to improve health care quality. The Commonwealth Fund 2019. www.commonwealthfund.org/publications/newsletter- article/using-patient-reported-outcomes-improve-health-care-quality . Accessed October 24, 2019.
30. Charlotte Kingsley SP. Patient-reported outcome measures and patient-reported experience measures. BJA Education. 2017;17:137-144.
31. Weldring T, Smith SM. Patient-Reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Services Insights. 2013;6:61-68.
32. Elwyn G, Barr PJ, Grande SW, et al. Developing CollaboRATE: A fast and frugal patient-reported measure of shared decision making in clinical encounters. Patient Educ Couns. 2013;93:102-107.
33. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
34. Rudick RA, Miller D, Clough JD, et al. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol. 1992;49:1237-1242.
35. Benito-Leon J, Morales JM, Rivera-Navarro J, Mitchell A. A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil. 2003;25:1291-1303.
36. RAND Corporation. 36-Item Short Form Survey (SF-36). [https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form.html . Accessed October 20, 2019.
37. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Medical Care. 1981;19:787-805.
38. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.
39. Kinkel RP, Laforet G, You X. Disease-related determinants of quality of life 10 years after clinically isolated syndrome. Int J MS Care. 2015;17:26-34.
40. Baumstarck-Barrau K, Simeoni MC, Reuter F, et al. Cognitive function and quality of life in multiple sclerosis patients: a cross-sectional study. BMC Neurology. 2011;11:17.
41. Samartzis L, Gavala E, Zoukos Y, et al. Perceived cognitive decline in multiple sclerosis impacts quality of life independently of depression. Rehabil Res Pract. 2014;2014:128751.
42. Vitkova M, Rosenberger J, Krokavcova M, et al. Health-related quality of life in multiple sclerosis patients with bladder, bowel and sexual dysfunction. Disabil Rehabil. 2014;36:987-992.
43. Khurana V, Sharma H, Afroz N, et al. Patient-reported outcomes in multiple sclerosis: a systematic comparison of available measures. Eur J Neurol. 2017;24:1099-1107.
44. Hobart J, Lamping D, Fitzpatrick R, et al. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001;124(Pt 5):962-973.
45. Lily O, McFadden E, Hensor E, et al. Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment. Multiple Sclerosis. 2006;12:808-813.
46. Ford HL, Gerry E, Tennant A, et al. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil. 2001;15:247-258.
47. Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 1996;47:129-139.
48. Gold SM, Heesen C, Schulz H, et al. Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Multiple Sclerosis. 2001;7:119-130.
49. Vickrey BG, Hays RD, Harooni R, et al. A health-related quality of life measure for multiple sclerosis. Qual Life Res. 1995;4:187-206.
50. Simeoni M, Auquier P, Fernandez O, et al. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Multiple Sclerosis. 2008;14:219-230.
51. Doward LC, McKenna SP, Meads DM, et al. The development of patient-reported outcome indices for multiple sclerosis (PRIMUS). Multiple Sclerosis. 2009;15:1092-1102.
52. Ozakbas S, Akdede BB, Kosehasanogullari G, et al. Difference between generic and multiple sclerosis-specific quality of life instruments regarding the assessment of treatment efficacy. J Neurol Sci. 2007;256:30-34.
53. Cella DF, Wiklund I, Shumaker SA, Aaronson NK. Integrating health-related quality of life into cross-national clinical trials. Qual Life Res. 1993;2:433-440.
54. Nowinski CJ, Miller DM, Cella D. Evolution of patient-reported outcomes and their role in multiple sclerosis clinical trials. Neurotherapeutics. 2017;14:934-944.
55. Cella D, Nowinski C, Peterman A, et al. The neurology quality-of-life measurement initiative. Arch Phys Med Rehabil. 2011;92(10 Suppl):S28-S36.
56. HealthMeasures: PROMIS. http://www.healthmeasures.net/explore-measurement-systems/promis . Accessed October 20, 2019.
57. Valderas JM, Ferrer M, Mendivil J, et al. Development of EMPRO: a tool for the standardized assessment of patient-reported outcome measures. Value Health. 2008;11:700-708.
58. Bach K, Martling C, Mork PJ, et al. Design of a clinician dashboard to facilitate co-decision making in the management of non-specific low back pain. J Intelligent Helath Syst. 2019;52:269-284.
59. Karami M, Safdari R, Rahimi A. Effective radiology dashboards: key research findings. Radiology Management. 2013;35:42-45.
60. Dowding D, Randell R, Gardner P, et al. Dashboards for improving patient care: review of the literature. Int J Med Informatic. 2015;84:87-100.
61. Mlaver E, Schnipper JL, Boxer RB, et al. User-centered collaborative design and development of an inpatient safety dashboard. Jt Comm J Qual Patient Saf. 2017;43:676-685.
62. Dowding D, Merrill J, Russell D. Using feedback intervention theory to guide clinical dashboard design. AMIA Annu Symp Proc. 2018;2018:395-403.
63. Hartzler AL, Izard JP, Dalkin BL, et al. Design and feasibility of integrating personalized PRO dashboards into prostate cancer care. J Am Med Inform Assoc. 2016;23:38-47.
64. Lavallee DC, Chenok KE, Love RM, et al. Incorporating patient-reported outcomes into health care to engage patients and enhance care. Health Affairs. 2016;35:575-582.
65. U.S. Centers for Medicare & Medicaid Services. Comprehensive Care for Joint Replacement Model. https://innovation.cms.gov/initiatives/CJR . Accessed August 3, 2019.
66. National Quality Forum. Patient-reported outcomes: Accessed August 3, 2019. http://www.qualityforum.org/Patient-Reported_Outcomes.aspx . Accessed October 20, 2019.
67. Institute of Medicine Roundtable on Evidence-Based Medicine. The National Academies Collection: Reports funded by National Institutes of Health. In: Olsen LA, Aisner D, McGinnis JM, eds. The Learning Healthcare System: Workshop Summary. Washington (DC): National Academies Press (US).National Academy of Sciences; 2007.
68. About Learning Health Systems: Agency for Healthcare Research and Quality. https://www.ahrq.gov/learning-health-systems/about.html . Accessed August 3, 2019.
69. Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. Washington (DC): National Academies Press; 2013.
70. Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press; 2001.
71. Oliver BJ, for the MS-CQI Investigators. The Multiple Sclerosis Continuous improvement collaborative: the first coproduction learning health system improvement science research collaborative for multiple sclerosis. The International Society for Quality in Health Care (ISQua) Annual International Conference; October 2019; Cape Town, South Africa.
72. Britto MT, Fuller SC, Kaplan HC, et al. Using a network organisational architecture to support the development of Learning Healthcare Systems. BMJ Qual Saf. 2018;27:937-946.
73. Care Centers: Cystic Fibrosis Foundation. https://www.cff.org/Care/Care-Centers/ . Accessed August 3, 2019.
74. Schechter MS, Fink AK, Homa K, Goss CH. The Cystic Fibrosis Foundation patient registry as a tool for use in quality improvement. BMJ Qual Saf. 2014;23(Suppl 1):i9-i14.
75. Mogayzel PJ, Dunitz J, Marrow LC, Hazle LA. Improving chronic care delivery and outcomes: the impact of the cystic fibrosis Care Center Network. BMJ Qual Saf. 2014;23(Suppl 1):i3-i8.
76. Godfrey MM, Oliver BJ. Accelerating the rate of improvement in cystic fibrosis care: contributions and insights of the learning and leadership collaborative. BMJ Qual Saf. 2014;23(Suppl 1):i23-i32.
77. Nelson EC, Godfrey MM. Quality by Design: A Clinical Microsystems Approach . San Francisco, California: Jossey-Bass; 2007.
78. Crohn’s & Colitis Foundation.Quality of Care: IBD Qorus: https:// www.crohnscolitisfoundation.org/research/ibd-qorus . Accessed October 23, 2019.
79. Johnson LC, Melmed GY, Nelson EC, et al. Fostering collaboration through creation of an ibd learning health system. Am J Gastroenterol. 2017;112:406-468.
80. Fernandez-Munoz JJ, Moron-Verdasco A, Cigaran-Mendez M, et al. Disability, quality of life, personality, cognitive and psychological variables associated with fatigue in patients with multiple sclerosis. Acta Neurologica Scandinavica. 2015;132:118-124.
81. Flachenecker P, Kumpfel T, Kallmann B, et al. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Multiple Sclerosis. 2002;8:523-526.
82. Tellez N, Rio J, Tintore M, et al. Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? Multiple Sclerosis. 2005;11:198-202.
83. Salter A, Fox RJ, Tyry T, et al. The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments. Mult Scler Relat Disord. 2019;31:165-72.
84. Solaro C, Trabucco E, Messmer Uccelli M. Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep. 2013;13:320.
85. Jawahar R, Oh U, Yang S, Lapane KL. A systematic review of pharmacological pain management in multiple sclerosis. Drugs. 2013;73:1711-1722.
86. Rintala A, Hakkinen A, Paltamaa J. Ten-year follow-up of health-related quality of life among ambulatory persons with multiple sclerosis at baseline. Qual Life Res. 2016;25:3119-3127.
87. Tepavcevic DK, Pekmezovic T, Stojsavljevic N, et al. Change in quality of life and predictors of change among patients with multiple sclerosis: a prospective cohort study. Qual Life Res. 2014;23:1027-1037.
88. DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs. 2003;63:153-166.
89. Marck CH, Jelinek PL, Weiland TJ, et al. Sexual function in multiple sclerosis and associations with demographic, disease and lifestyle characteristics: an international cross-sectional study. BMC Neurology. 2016;16:210.
90. Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clinical Cases. 2015;3:545-555.
91. National Multiple Sclerosis Society. Disease-modifying therapies for MS. 2018.
92. Rudick RA, Panzara MA. Natalizumab for the treatment of relapsing multiple sclerosis. Biologics. 2008;2:189-199.
93. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59:679-687.
94. Patti F, Pappalardo A, Montanari E, et al. Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: results from a longitudinal study. J Neurol Sci. 2014;337:180-185.
95. Novartis. Exploring the efficacy and safety of Siponimod in patients with secondary progressive multiple sclerosis (EXPAND). Available from clinicaltrials.gov/ct2/show/NCT01665144 . NLM identifier: NCT01665144.
96. Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014;5:e45.
97. Jongen PJ. Health-related quality of life in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs. 2017;31:585-602.
98. Coretti S, Ruggeri M, McNamee P. The minimum clinically important difference for EQ-5D index: a critical review. Expert Rev Pharmacoecon Outcomes Res. 2014;14:221-233.
99. Clinical Review Report: Ocrelizumab (Ocrevus). CADTH Common Drug Review. 2018:Appendix 4, Validity of Outcome Measures.
100. iCounquer MS; Empowering patients: how individuals with ms are contributing to the fight to find a cure: 2018. https://www.iconquerms.org/empowering-patients-how-individuals-ms-are-contributing-fight-find-cure . Accessed October 23, 2019.
101. K M. Accelerated Cure Project Announces Collaboration with EMD Serono to Advance Patient-Focused Drug Development in Multiple Sclerosis2018. https://www.iconquerms.org/accelerated-cure- project-announces-collaboration-emd-serono-advance-patient-focused-drug-development . Accessed October 24, 2019.
102. Bebo BF Jr, Fox RJ, Lee K, et al. Landscape of MS patient cohorts and registries: Recommendations for maximizing impact. Multiple Sclerosis. 2018;24:579-586.
103. Hedstrom AK, Hillert J, Olsson T, Alfredsson L. Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk. JAMA Neurology. 2014;71:300-305.
104. Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology. 2009;73:696-701.
105. Hedstrom AK, Akerstedt T, Hillert J, et al. Shift work at young age is associated with increased risk for multiple sclerosis. Ann Neurol. 2011;70:733-741.
106. Hadjimichael O, Vollmer T, Oleen-Burkey M. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes. 2008;6:100.
107. Fox RJ, Salter AR, Tyry T, et al. Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the North American research committee on multiple sclerosis database. Int J MS Care. 2013;15:194-201.
108. Reeve BB, Wyrwich KW, Wu AW, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res. 2013;22:1889-1905.
109. Jacobs LD, Wende KE, Brownscheidle CM, et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Multiple Sclerosis. 1999;5:369-376.
110. Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, et al. Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Multiple Sclerosis. 2003;9:293-298.
111. Raffel J, Wallace A, Gveric D, et al. Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29. PLoS Med. 2017;14:e1002346.
112. Vaughn CB, Kavak KS, Dwyer MG, et al. Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium. Multiple Sclerosis. 2018:1352458518816619.
113. Alroughani RA, Akhtar S, Ahmed SF, Al-Hashel JY. Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a nation-wide cohort. Int J Neuroscience. 2015;125:831-837.
114. Dolan JG, Veazie PJ, Russ AJ. Development and initial evaluation of a treatment decision dashboard. BMC Med Inform Decision Mak. 2013;13:51.
115. Stuifbergen AK, Becker H, Blozis S, et al. A randomized clinical trial of a wellness intervention for women with multiple sclerosis. Arch Phys Med Rehabil. 2003;84:467-476.
116. Finkelstein J, Martin C, Bhushan A, et al. Feasibility of computer-assisted education in patients with multiple sclerosis. In: Proceedings of the IEEE Symposium on Computer-Based Medical Systems. Bethesda, MD; 2004.
117. Batalden P. Getting more health from healthcare: quality improvement must acknowledge patient coproduction—an essay by Paul Batalden. BMJ. 2018;362:k3617.
118. Batalden PB, Davidoff F. What is “quality improvement” and how can it transform healthcare? Qual Saf Health Care. 2007;16:2-3.
119. Ovretveit J, Zubkoff L, Nelson EC, et al. Using patient-reported outcome measurement to improve patient care. Int J Qual Health Care. 2017;29:874-879.
120. Prodinger B, Taylor P. Improving quality of care through patient-reported outcome measures (PROMs): expert interviews using the NHS PROMs Programme and the Swedish quality registers for knee and hip arthroplasty as examples. BMC Health Services Res. 2018;18:87.
121. Prinsen CA, Vohra S, Rose MR, et al. How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” – a practical guideline. Trials. 2016;17:449.
122. NINDS. NINDS Common Data Elements: Streamline Your Neuroscience Clinical Research National Institute of Health. https://www.commondataelements.ninds.nih.gov/#page=Default . Accessed October 23, 2019.
123. Francis DO, McPheeters ML, Noud M, et al. Checklist to operationalize measurement characteristics of patient-reported outcome measures. Systematic Rev. 2016;5:129.
124. National Quality Forum. Patient-reported outcomes (PROs) in performance measurement. 2013. https://www.qualityforum.org/Publications/2012/12/Patient-Reported_Outcomes_in_Performance_Measurement.aspx . Accessed October 15, 2019.
125. Dawson J, Doll H, Fitzpatrick R, et al. The routine use of patient reported outcome measures in healthcare settings. BMJ. 2010;340:c186.
126. Aaronson N ET, Greenlhalgh J, Halyard M, et al. User’s guide to implementation of patient reported outcomes assessment in clinical practice. International Society for Quality of Life. 2015.
127. Chan EKH, Edwards TC, Haywood K, et al. Implementing patient-reported outcomes mesaures in clinical practice: a companion guide to the ISOQOL user’s guide. Qual Life Res. 2018;28:621-627.
128. Snyder CF, Wu AW, Miller RS, et al. The role of informatics in promoting patient-centered care. Cancer J. 2011;17:211-218
129. Osborn R, Moulds D, Schneider EC, et al. Primary care physicians in ten countries report challenges caring for patients with complex health needs. Health Affairs. 2015;34:2104-2112.
130. Wu AW, Kharrazi H, Boulware LE, Snyder CF. Measure once, cut 0wice--adding patient-reported outcome measures to the electronic health record for comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S12-S20.
131. Trojano M, Bergamaschi R, Amato MP, et al. The Italian multiple sclerosis register. Neurol Sci. 2019;40:155-165.
132. Moorhead SA, Hazlett DE, Harrison L, et al. A new dimension of health care: systematic review of the uses, benefits, and limitations of social media for health communication. J Med Internet Res. 2013;15:e85.
133. Luigi L, Francesco B, Marcello M, et al. e-Health and multiple sclerosis: An update. Multiple Sclerosis J. 2018;24:1657-1664.
134. Marrie RA, Leung S, Tyry T, et al. Use of eHealth and mHealth technology by persons with multiple sclerosis. Mult Scler Relat Dis. 2019;27:13-19.
135. Giunti G, Kool J, Rivera Romero O, Dorronzoro Zubiete E. Exploring the specific needs of persons with multiple sclerosis for mhealth solutions for physical activity: mixed-methods study. JMIR Mhealth Uhealth. 2018;6:e37.
136. Spooner KK, Salemi JL, Salihu HM, Zoorob RJ. eHealth patient-provider communication in the United States: interest, inequalities, and predictors. J Am Med Inform Assoc. 2017;24(e1):e18-e27.
137. Safdar N, Abbo LM, Knobloch MJ, Seo SK. Research methods in healthcare epidemiology: survey and qualitative research. Infect Control Hosp Epidemiol. 2016;37:1272-1277.
138. Rolstad S, Adler J, Rydén A. Response burden and questionnaire length: is shorter better? A review and meta-analysis. Value Health. 2011;14:1101-1108.
139. Chiu C, Bishop M, Pionke JJ, et al. Barriers to the accessibility and continuity of health-care services in people with multiple sclerosis: a literature review. Int J MS Care. 2017;19:313-321.
140. Atreja A, Mehta N, Miller D, et al. One size does not fit all: using qualitative methods to inform the development of an Internet portal for multiple sclerosis patients. AMIA Annu Symp Proc Symp. 2005:16-20.
141. Snyder CF, Blackford AL, Brahmer JR, et al. Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30. Qual Life Res. 2010;19:837-845.
142. de Vet HC, Terwee CB. The minimal detectable change should not replace the minimal important difference. J Clin Epidemiol. 2010;63:804-805.
143. Snyder CF, Aaronson NK, Choucair AK, et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life. 2012;21:1305-1314.
144. Myla DG, Melanie DW, Robert WM, et al. Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale. Multiple Sclerosis J. 2017;23:1405-1414.
145. van Munster CEP, Uitdehaag BMJ. Outcome measures in clinical trials for multiple sclerosis. CNS Drugs. 2017;31:217-236.
146. Snyder CF, Jensen R, Courtin SO, Wu AW. PatientViewpoint: a website for patient-reported outcomes assessment. Quality Life Res. 2009;18:793-800.
147. Snyder CF, Smith KC, Bantug ET, et al. What do these scores mean? Presenting patient-reported outcomes data to patients and clinicians to improve interpretability. Cancer. 2017;123:1848-1859.
148. Squitieri L, Bozic KJ, Pusic AL. The role of patient-reported outcome measures in value-based payment reform. Value Health. 2017;20:834-836.
149. Boyce MB, Browne JP. The effectiveness of providing peer benchmarked feedback to hip replacement surgeons based on patient-reported outcome measures—results from the PROFILE trial: a cluster randomised controlled study. BMJ Open. 2015;5:e008325.